-
Je něco špatně v tomto záznamu ?
Maintenance electroconvulsive therapy in schizophrenia
J. Krepela, L. Hosak, B. Pachlova, M. Hrdlicka,
Jazyk angličtina Země Chorvatsko
Typ dokumentu časopisecké články, pozorovací studie
Grantová podpora
NV16-27243A
MZ0
CEP - Centrální evidence projektů
Digitální knihovna NLK
Plný text - Článek
NLK
Free Medical Journals
od 2008
Medline Complete (EBSCOhost)
od 2011-12-01
PubMed
30948691
DOI
10.24869/psyd.2019.62
Knihovny.cz E-zdroje
- MeSH
- elektrokonvulzívní terapie * MeSH
- katatonie MeSH
- lidé MeSH
- retrospektivní studie MeSH
- schizofrenie * terapie MeSH
- výsledek terapie MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- pozorovací studie MeSH
- Geografické názvy
- Česká republika MeSH
BACKGROUND: The aim of our retrospective naturalistic observational study was to describe the use of maintenance electroconvulsive therapy (M-ECT) in chronic pharmacoresistant schizophrenia. SUBJECTS AND METHODS: We delineated 19 cases of chronic pharmacoresistant schizophrenia (females N=12) recently treated with maintenance electroconvulsive therapy at the Havlickuv Brod Psychiatric Hospital in the Czech Republic. Demographic, clinical and treatment variables were recorded. RESULTS: M-ECT, when applied weekly to monthly mostly over a period of several years, was of no benefit in the treatment of chronic hallucinations and/or delusions. However, it did prove beneficial (p<0.001) in removing chronic serious symptoms like suicidal or violent behavior, automutilation, refusal of food or liquids, stupor or catatonia. Even though almost all of our patients remained hospitalized, we were nonetheless able to transfer them to an unlocked psychiatric ward and let them out for walks or occupational therapy with almost no need for using restraint. No serious adverse side effects of M-ECT were found. CONCLUSIONS: Our study is limited by using only one simple standardized measurement (Clinical Global Impression - Severity) that was retrospective. Another limitation of our retrospective study was that the subjects had not been regularly tested for their cognitive functions. According to our results, M-ECT mitigates the impact of the disease and improves social functioning of the patients. M-ECT does not treat chronic schizophrenia but does make the lives of patients more tolerable. We suggest further research into M-ECT and its clinical application in chronic pharmacoresistant schizophrenia.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19034658
- 003
- CZ-PrNML
- 005
- 20191017090344.0
- 007
- ta
- 008
- 191007s2019 ci f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.24869/psyd.2019.62 $2 doi
- 035 __
- $a (PubMed)30948691
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ci
- 100 1_
- $a Krepela, Josef $u Psychiatric Hospital, Havlickuv Brod, Czech Republic.
- 245 10
- $a Maintenance electroconvulsive therapy in schizophrenia / $c J. Krepela, L. Hosak, B. Pachlova, M. Hrdlicka,
- 520 9_
- $a BACKGROUND: The aim of our retrospective naturalistic observational study was to describe the use of maintenance electroconvulsive therapy (M-ECT) in chronic pharmacoresistant schizophrenia. SUBJECTS AND METHODS: We delineated 19 cases of chronic pharmacoresistant schizophrenia (females N=12) recently treated with maintenance electroconvulsive therapy at the Havlickuv Brod Psychiatric Hospital in the Czech Republic. Demographic, clinical and treatment variables were recorded. RESULTS: M-ECT, when applied weekly to monthly mostly over a period of several years, was of no benefit in the treatment of chronic hallucinations and/or delusions. However, it did prove beneficial (p<0.001) in removing chronic serious symptoms like suicidal or violent behavior, automutilation, refusal of food or liquids, stupor or catatonia. Even though almost all of our patients remained hospitalized, we were nonetheless able to transfer them to an unlocked psychiatric ward and let them out for walks or occupational therapy with almost no need for using restraint. No serious adverse side effects of M-ECT were found. CONCLUSIONS: Our study is limited by using only one simple standardized measurement (Clinical Global Impression - Severity) that was retrospective. Another limitation of our retrospective study was that the subjects had not been regularly tested for their cognitive functions. According to our results, M-ECT mitigates the impact of the disease and improves social functioning of the patients. M-ECT does not treat chronic schizophrenia but does make the lives of patients more tolerable. We suggest further research into M-ECT and its clinical application in chronic pharmacoresistant schizophrenia.
- 650 _2
- $a katatonie $7 D002389
- 650 12
- $a elektrokonvulzívní terapie $7 D004565
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 12
- $a schizofrenie $x terapie $7 D012559
- 650 _2
- $a výsledek terapie $7 D016896
- 651 _2
- $a Česká republika $7 D018153
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a pozorovací studie $7 D064888
- 700 1_
- $a Hosak, Ladislav
- 700 1_
- $a Pachlova, Barbora
- 700 1_
- $a Hrdlicka, Michal
- 773 0_
- $w MED00006897 $t Psychiatria Danubina $x 0353-5053 $g Roč. 31, č. 1 (2019), s. 62-68
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30948691 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20191007 $b ABA008
- 991 __
- $a 20191017090812 $b ABA008
- 999 __
- $a ok $b bmc $g 1451318 $s 1073208
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 31 $c 1 $d 62-68 $e - $i 0353-5053 $m Psychiatria Danubina $n Psychiatr Danub $x MED00006897
- GRA __
- $a NV16-27243A $p MZ0
- LZP __
- $a Pubmed-20191007